Premium
OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA‐101 TRIAL, A LYSA GROUP STUDY
Author(s) -
Le Gouill S.,
BeldiFerchiou A.,
Cacheux V.,
Salles G.,
Canioni D.,
BodetMilin C.,
Alcantara M.,
Delwail V.,
Gastinne T.,
Thieblemont C.,
Maisonneuve H.,
Lamy de la Chapelle T.,
Oberic l.,
Bouabdallah K.,
Ribrag V.,
DelfauLarue M.,
Macintyre E.,
Hermine O.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.14_2629
Subject(s) - obinutuzumab , medicine , dhap , autologous stem cell transplantation , oncology , rituximab , regimen , transplantation , chemotherapy regimen , aggressive lymphoma , chemotherapy , lymphoma , biology , biochemistry , enzyme